Company: SCLXW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047800
Chunk: 230

Company: Scilex Holding Co
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 230
---

    (390
    )

    Total ZTlido

    16,148

    15,610

    538

    ELYXYB

    Cost of Revenue

    181

    36

    145

    Cost of Revenue - Royalties

    341

    35

    306

    Total ELYXYB

    522

    71

    451

    GLOPERBA

    Cost of Revenue

    19

    —

    19

    Total GLOPERBA

    19

    —

    19

    Total Cost of Revenue
     
    $
    16,689

    $
    15,681

    $
    1,008

Cost of revenue for the years ended December 31, 2024 and 2023 was $16.7 million and $15.7 million, respectively. Cost of revenue for ZTlido increased by $0.5 million due to higher royalties primarily driven by an increase in gross product sales by approximately 6%, partially offset by a decrease due to favorable foreign currency exchange rate fluctuations affecting purchases from our foreign supplier, Itochu, and decrease in logistics costs due to the absence of air shipments in 2024 compared to 2023. Cost of revenue for ELYXYB increased by $0.5 million and was primarily due to the increase in gross product sales by approximately 49% with the sales commencing in April 2023. GLOPERBA sales commenced in June 2024.

 127

Research and Development Expenses

The following table summarizes research and development expenses by project for the years ended December 31, 2024 and 2023 (in thousands):

    Year Ended December 31,

    2024

    2023

    Increase (Decrease)

    SP-102

    Contracted R&D
     
    $
    1,160

    $
    1,229

    $
    (69
    )

    Personnel

    467

    254

    213

    Other

    57

    64

    (7
    )

    Total SP-102

    1,684

    1,547

    137

    SP-103

    Contracted R&D

    2,472

    4,270

    (1,798
    )

    Personnel